Despite this limitation, studies that have implemented CSF collection from patients during the progression of their MS have uncovered elevated levels of NF-L, a potential biomarker for axonal damage and a possible prognostic measure of progressive MS (Figure 1) [56]. Here, NEFL is linked to myeloid sarcoma.